

Virginia Hahn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2671561/publications.pdf>

Version: 2024-02-01

18
papers

1,410
citations

687363

13
h-index

888059

17
g-index

20
all docs

20
docs citations

20
times ranked

2680
citing authors

#	ARTICLE	IF	CITATIONS
1	Nitrosative stress drives heart failure with preserved ejection fraction. <i>Nature</i> , 2019, 568, 351-356.	27.8	492
2	Cancer Therapy-Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies. <i>Journal of the American Heart Association</i> , 2014, 3, e000665.	3.7	221
3	Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1551-1556.	7.1	164
4	Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab. <i>Clinical Chemistry</i> , 2015, 61, 1164-1172.	3.2	129
5	Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2021, 143, 120-134.	1.6	123
6	Prevention of PKG1 α oxidation augments cardioprotection in the stressed heart. <i>Journal of Clinical Investigation</i> , 2015, 125, 2468-2472.	8.2	64
7	Osteopontin Promotes Left Ventricular Diastolic Dysfunction Through a Mitochondrial Pathway. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2705-2718.	2.8	41
8	Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction. <i>Circulation Research</i> , 2019, 124, 1618-1632.	4.5	39
9	Heart Failure With Targeted Cancer Therapies. <i>Circulation Research</i> , 2021, 128, 1576-1593.	4.5	33
10	Reduced Right Ventricular Sarcomere Contractility in Heart Failure With Preserved Ejection Fraction and Severe Obesity. <i>Circulation</i> , 2021, 143, 965-967.	1.6	32
11	CHIP phosphorylation by protein kinase G enhances protein quality control and attenuates cardiac ischemic injury. <i>Nature Communications</i> , 2020, 11, 5237.	12.8	24
12	Tetrahydrobiopterin Protects Against Hypertrophic Heart Disease Independent of Myocardial Nitric Oxide Synthase Coupling. <i>Journal of the American Heart Association</i> , 2016, 5, e003208.	3.7	21
13	Acute Hemodynamic Effects and Tolerability of Phosphodiesterase-1 Inhibition With ITI-214 in Human Systolic Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e008236.	3.9	15
14	A Report of Accelerated Coronary Artery Disease Associated with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy. <i>Case Reports in Cardiology</i> , 2015, 1-3.	0.2	6
15	Under-Enrollment of Obese Heart Failure with Preserved Ejection Fraction Patients in Major HFpEF Clinical Trials. <i>Journal of Cardiac Failure</i> , 2022, 28, 723-731.	1.7	3
16	Obesity-induced cardiac dysfunction: pre-natal vs. post-natal nurture. <i>Cardiovascular Research</i> , 2018, 114, 1308-1309.	3.8	1
17	Tackling the Heterogeneity of Heart Failure with Preserved Ejection Fraction using Proteomic Profiling. <i>Journal of Cardiac Failure</i> , 2022, , .	1.7	0
18	Cystatin C Predicts Adverse Outcomes In Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, S80-S81.	1.7	0